Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

First Immunosequencing–Based Diagnostic Cleared by FDA

clonoSEQ receives FDA clearance for the detection and monitoring of measurable residual disease (MRD) in patients with multiple myeloma and acute lymphoblastic leukemia.